Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20%[23] - The company's operating revenue for the first half of the year reached ¥155,735,532.15, a year-on-year increase of 137.48% compared to ¥65,578,360.74 in the same period last year[30] - Net profit attributable to shareholders was ¥80,637,529.40, reflecting a significant increase of 190.02% from ¥27,803,832.00 in the previous year[30] - The net cash flow from operating activities increased by 60.44%, amounting to ¥55,348,502.37, compared to ¥34,498,788.76 in the same period last year[30] - Basic earnings per share increased to ¥1.34, a growth of 116.13% compared to ¥0.62 in the same period last year[34] - The comprehensive gross margin improved to 84.69%, up by 3.3 percentage points from the previous year, driven by increased order volume and changes in product structure[35] - The company achieved a total R&D investment of ¥18,130,676.38, representing an 86.25% increase compared to the previous period[59] - The company achieved a revenue of 155.74 million yuan for the period from January 1 to June 30, 2021, representing a growth of 137.48% compared to the same period in 2020[72] - The net profit attributable to shareholders for the same period was CNY 80.64 million, an increase of 190.02% compared to the previous year[80] - The comprehensive gross profit margin for the reporting period was 84.69%, up by 3.3 percentage points from the same period last year[82] Research and Development - Research and development expenses increased by 30% to RMB 50 million, focusing on new technologies and product innovations[23] - Research and development expenses rose to ¥1,800,000, representing an 86.25% increase year-on-year, indicating a strong commitment to innovation[35] - The company has expanded its R&D team to 35 members, with R&D personnel now constituting 20.96% of the total workforce[67] - The company has made significant breakthroughs in low molecular weight PEG and cationic lipids for gene delivery during the reporting period[57] - The company is actively expanding its product line in the PEG derivatives sector, focusing on market potential and technological advancements[69] - The company completed the optimization and improvement of 16 derivative product processes and developed 48 new structural derivatives[71] - The company holds a total of 91 patents, with 16 new patents obtained during the reporting period, including 8 invention patents[58] Market Expansion and Strategy - The company expects a revenue growth forecast of 25% for the second half of 2021, driven by new product launches and market expansion strategies[23] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[23] - A strategic acquisition of a complementary technology firm is under consideration to enhance product offerings and market competitiveness[23] - JianKai Technology has established a direct sales model for both domestic and international markets, targeting well-known pharmaceutical companies and research institutions[47] - The company is actively expanding its market presence and enhancing its brand recognition through participation in exhibitions and targeted marketing strategies[47] Financial Management and Shareholder Policies - The company has no plans for dividend distribution for this reporting period, focusing instead on reinvestment into growth initiatives[23] - The profit distribution policy emphasizes reasonable returns to investors, maintaining continuity and stability, with cash dividends prioritized when conditions allow[191] - The company commits to a cash dividend of no less than 10% of the annual distributable profit and a cumulative distribution of no less than 30% of the average annual distributable profit over the last three years[194] - The company will strictly manage the use of raised funds to ensure they are utilized effectively for their intended purposes[185] - The company will establish a stable profit distribution policy to enhance the investor return mechanism[185] Environmental and Safety Compliance - The company has established a safety and environmental health committee directly under the general manager to oversee daily safety production and environmental protection management[137] - Environmental monitoring includes online detection and regular monitoring by qualified third parties, ensuring compliance with environmental standards[134] - The company has implemented various environmental management systems, including hazardous waste management and environmental hazard rectification[137] - No administrative penalties were imposed on the company during the reporting period for environmental issues[137] Corporate Governance and Shareholder Commitments - The company has committed to a 36-month lock-up period for shares held by major shareholders following the IPO, with an extension of 6 months if the stock price falls below the IPO price for 20 consecutive trading days within the first 6 months[140] - The company will ensure compliance with the Shanghai Stock Exchange's rules regarding shareholding and transfer limitations, including public apologies and corrective actions for any breaches[146] - The company has established a clear framework for managing share transfers and ensuring accountability among its major shareholders and executives[149] - The company will take measures such as disclosing reasons for unfulfilled commitments and compensating investors for losses caused by such failures[199]

Financial Performance - Operating revenue surged by 158.77% to CNY 69,918,824.65 year-on-year[12] - Net profit attributable to shareholders rose by 229.52% to CNY 35,993,273.76 compared to the same period last year[12] - Basic earnings per share increased by 150.00% to CNY 0.60 compared to the same period last year[15] - Total revenue for Q1 2021 reached ¥69,918,824.65, a significant increase from ¥27,019,555.82 in Q1 2020, representing a growth of approximately 159.5%[46] - Net profit for Q1 2021 was ¥35,993,273.76, compared to ¥10,922,899.96 in Q1 2020, marking an increase of about 229.5%[46] - Operating profit for Q1 2021 was ¥41,925,586.26, compared to ¥12,650,445.57 in Q1 2020, indicating an increase of approximately 230.5%[46] - Total comprehensive income for Q1 2021 was ¥35,552,598.07, compared to ¥11,180,337.22 in Q1 2020, reflecting an increase of approximately 218.5%[48] Cash Flow - Net cash flow from operating activities reached CNY 6,243,487.18, a significant recovery from a negative cash flow of CNY -2,082,630.90 in the previous year[12] - Cash flow from operating activities totaled 5,409,702.26 RMB, significantly higher than 1,949,731.18 RMB in the previous year, marking an increase of 177%[51] - Cash inflow from operating activities totaled ¥150,705,302.53 in Q1 2021, compared to ¥30,078,702.51 in Q1 2020[49] - The net cash flow from investing activities was -329,617,861.24 RMB, worsening from -111,943.01 RMB year-over-year[51] Assets and Liabilities - Total assets increased by 6.59% to CNY 959,920,354.30 compared to the end of the previous year[12] - Current assets totaled ¥827,235,566.31, up from ¥785,063,564.10, indicating an increase of about 5.7% year-over-year[36] - Total liabilities amounted to ¥63,475,457.92, up from ¥44,368,069.83, reflecting an increase of about 43%[39] - Shareholders' equity reached ¥896,444,896.38, compared to ¥856,243,364.98, indicating a growth of approximately 4.7%[39] - The company reported a significant increase in contract liabilities, which rose to ¥13,347,437.09 from ¥4,855,882.81, representing an increase of about 175%[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 3,788[16] - The largest shareholder, Xuan Zhao, holds 24.78% of the shares, totaling 14,866,610 shares[16] Research and Development - R&D expenditure as a percentage of operating revenue decreased by 7.76 percentage points to 8.73%[15] - Research and development expenses increased by 37.02% to ¥6,103,116.00, driven by higher labor and outsourcing costs[28] - Research and development expenses in Q1 2021 totaled ¥6,103,116.00, up from ¥4,454,023.05 in Q1 2020, representing a rise of about 37%[46] Government Subsidies - The company reported a government subsidy of CNY 26,147.58 related to its normal business operations[15] Inventory and Receivables - Accounts receivable increased by 84.21% to ¥84,938,751.66, reflecting a rise in operating income[22] - Prepayments surged by 741.57% to ¥21,423,173.15, primarily due to the investment project in medical polyethylene glycol[22] - Inventory increased to ¥26,557,562.66 from ¥23,436,550.08, showing a growth of approximately 9%[36] Capital Structure - The company maintained a stable capital reserve of ¥611,039,649.20, slightly increasing from ¥606,390,715.87[39] - The company has a total of $606.39 million in capital reserves, showcasing robust financial health[61] - Shareholders' equity stood at approximately $721.26 million, reflecting a stable capital structure[61] Other Financial Metrics - The weighted average return on net assets decreased by 0.71 percentage points to 4.12%[12] - The company reported a 243.40% increase in income tax expenses to ¥5,932,312.50, attributed to higher sales revenue and total profit[30] - The company experienced a credit impairment loss of ¥1,750,060.07 in Q1 2021, compared to a loss of ¥364,519.88 in Q1 2020, reflecting a deterioration in credit quality[46]

2020 年年度报告 公司代码：688356 公司简称：键凯科技 JenKem Technology 北京键凯科技股份有限公司 2020 年年度报告 1 / 160 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅本 报告第四节"经营情况讨论与分析"。 三、 公司全体董事出席董事会会议。 四、 普华永道中天会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 五、 公司负责人赵宣、主管会计工作负责人韩磊及会计机构负责人（会计主管人员）李春雷声明： 保证年度报告中财务报告的真实、准确、完整。 六、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年利润分配预案为：公司拟以实施2020年度分红派息股权登记日的总股本为基数， 向全体股东每10股派发现金红利4.29元（含税），预计派发现金红利总额为25,740,000.00元，占 公司2020年度 ...

2020 年第三季度报告 公司代码：688356 公司简称：键凯科技 北京键凯科技股份有限公司 2020 年第三季度报告 1 / 28 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 11[ 重要事项 四、 附录 目录 2 / 28 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人 XUAN ZHAO、主管会计工作负责人韩磊及会计机构负责人（会计主管人员）何炜 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------|------------------------------|--------------------------------------|------------- ...